Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-12-08

FDA Approved: IRBESARTAN — Supplemental Application (NorthStar RxLLC)

View source ↗

Summary

The FDA approved a supplemental application for irbesartan from NorthStar RxLLC, authorizing changes to an existing generic product under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Irbesartan (irbesartan)

Snippet

SUPPL AP for IRBESARTAN (IRBESARTAN)